Early Progressive Disease Predicts Poor Outcomes of Second-line VEGFR Tyrosine Kinase Inhibitor Therapy After First-line Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma
Anticancer Research · 2026
DOI: 10.21873/anticanres.18144 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Nobuki Furubayashi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan nobumduro@gmail.com. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Ipilimumab, Nivolumab, Kidney Neoplasms.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan nobumduro@gmail.com.
- Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan.
Zitieren
APA
Furubayashi, N., Tsujita, J., Takayama, A., Shiraishi, Y., Nakamura, M., & Negishi, T. (2026). Early Progressive Disease Predicts Poor Outcomes of Second-line VEGFR Tyrosine Kinase Inhibitor Therapy After First-line Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.18144
Vancouver
Furubayashi N, Tsujita J, Takayama A, Shiraishi Y, Nakamura M, Negishi T. Early Progressive Disease Predicts Poor Outcomes of Second-line VEGFR Tyrosine Kinase Inhibitor Therapy After First-line Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma. Anticancer Research. 2026. doi:10.21873/anticanres.18144
BibTeX
@article{Furubayashi2026,
author = {Furubayashi, Nobuki and Tsujita, Jiro and Takayama, Azusa and Shiraishi, Yuta and Nakamura, Motonobu and Negishi, Takahito},
title = {Early Progressive Disease Predicts Poor Outcomes of Second-line VEGFR Tyrosine Kinase Inhibitor Therapy After First-line Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.18144}
}
EUVIMED